TC Biopharm (NASDAQ:TCBPW) Stock Price Down 29.5%
TC Biopharm (NASDAQ:TCBPW) Stock Price Down 29.5%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price was down 29.5% during trading on Wednesday . The stock traded as low as $0.12 and last traded at $0.14. Approximately 15,304 shares changed hands during trading, a decline of 77% from the average daily volume of 67,568 shares. The stock had previously closed at $0.20.
TC Biopharm Trading Up 41.8 %
The firm's 50-day moving average price is $0.13 and its 200 day moving average price is $0.18.
Get TC Biopharm alerts:Institutional Inflows and Outflows
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC purchased a new position in shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 235,294 shares of the company's stock, valued at approximately $117,000.
About TC Biopharm
(Get Rating)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
Featured Articles
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
- Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price was down 29.5% during trading on Wednesday . The stock traded as low as $0.12 and last traded at $0.14. Approximately 15,304 shares changed hands during trading, a decline of 77% from the average daily volume of 67,568 shares. The stock had previously closed at $0.20.
TC 生物製藥 (控股) 有限公司 (NASDAQ: TCBPW — 獲得評級) 的股價下跌 29.5% 在週三交易期間.該股票的交易價格低至 0.12 美元，最後交易價格為 0.14 美元。大約 15,304 股在交易過程中轉手，較 67,568 股的平均每日成交量下降了 77%。該股票以前已收盤 0.20 美元。
TC Biopharm Trading Up 41.8 %
TC 生物製藥交易增長 41.8%
The firm's 50-day moving average price is $0.13 and its 200 day moving average price is $0.18.
該公司的 50 天移動平均價格為 0.13 美元，200 日移動平均價格為 0.18 美元。
Institutional Inflows and Outflows
機構流入和流出
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC purchased a new position in shares of TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 235,294 shares of the company's stock, valued at approximately $117,000.
對沖基金最近買入了 TC 生物製藥股票的新股份。根據其最近向證券交易委員會（SEC）提交的 13F 文件，南大哈拉資本管理有限責任公司在第一季度購買了 TC 生物製藥（控股）有限公司（NASDAQ：TCBPW-獲得評級）的股份的新位置。該基金購入了該公司股票的 235,294 股，價值約為 11 萬美元。
About TC Biopharm
關於 TC 生物製藥
(Get Rating)
(取得評分)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
TC 生物醫藥（控股）有限公司是一家臨床階段生物製藥公司，致力於開發基於同種異體伽瑪三角量 T 細胞平台的免疫治療產品。其產品管線包括用於治療急性髓細胞白血病的未改性細胞療法；用於治療 COVID-19 的免疫性細胞療法；用於治療的未改性細胞療法；用於 GI 道癌症治療的 TCB009；以及作為異體共生刺激 GD-T CAR 臨床前藥物候選藥物的 TCB005/TCB006，以及針對各種腫瘤類型表達的抗原的 TCB005/TCB006。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
- Analysts Holding As Pfizer Waits On Two Phase 3 Studies
- 索取有關 TC 生物製藥研究報告的免費副本
- 減少收入減少，沉重的債務負擔
- 什麼是必需消費股？
- Rocky 品牌股息是否適合您的投資組合？
- 超越肉湯不是超越希望
- 作為輝瑞公司等待兩個階段 3 研究的分析師
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
接收 TC 生物製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 TC 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧